Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 541 | Dulaglutide 0.75mg Solution for Injection in Pre-Filled Pen | A10BJ05-000-P50-01-xxx | A* | Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: • in addition to other glucose lowering medicinal products for the treatment of diabetes. | i. HbA1c > 8.0% while on ≥2 Oral Glucose Lowering Drugs (OGLDs) and basal insulin AND ii. BMI > 30 kg/m2 AND iii. Very High CV Risk based on European Society of Cardiology (ESC) 2023 Risk Category: a. Clinically established ASCVD or b. Severe TOD (eGFR <45 mL/min/1.73m2 irrespective of albuminuria; or eGFR 45–59 mL/min/1.73m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at least three different sites or c. 10-year CVD risk ≥20% using SCORE2-Diabetes iv. To be prescribed by Endocrinologists only | Monotherapy: The recommended dose is 0.75 mg once weekly. Add-on therapy: The recommended dose is 1.5 mg once weekly. For potentially vulnerable populations 0.75 mg once weekly can be considered as a starting dose. |
| 542 | Dulaglutide 1.5mg Solution for Injection in Pre-Filled Pen | A10BJ05-000-P50-02-xxx | A* | Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: • in addition to other glucose lowering medicinal products for the treatment of diabetes. | i. HbA1c > 8.0% while on ≥2 Oral Glucose Lowering Drugs (OGLDs) and basal insulin AND ii. BMI > 30 kg/m2 AND iii. Very High CV Risk based on European Society of Cardiology (ESC) 2023 Risk Category: a. Clinically established ASCVD or b. Severe TOD (eGFR <45 mL/min/1.73m2 irrespective of albuminuria; or eGFR 45–59 mL/min/1.73m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at least three different sites or c. 10-year CVD risk ≥20% using SCORE2-Diabetes iv. To be prescribed by Endocrinologists only | Monotherapy: The recommended dose is 0.75 mg once weekly. Add-on therapy: The recommended dose is 1.5 mg once weekly. For potentially vulnerable populations 0.75 mg once weekly can be considered as a starting dose. |
| 543 | Duloxetine 30 mg Capsule | N06AX21110C1001XX | A* | i) Major depressive disorder ii) Diabetic peripheral neuropathic pain iii) Generalised Anxiety Disorder | i) & ii) ADULT: 60 mg once daily up to a maximum dose of 120mg/day (in divided doses) CHILD and ADOLESCENT under 18 years not recommended iii) Generalised Anxiety: Initial dose: 30 mg OD with or without food Maintenance dose: 60 mg OD | |
| 544 | Duloxetine 60 mg Capsule | N06AX21110C1002XX | A* | i) Major depressive disorder ii) Diabetic peripheral neuropathic pain iii) Generalised Anxiety Disorder | i) & ii) ADULT: 60 mg once daily up to a maximum dose of 120mg/day (in divided doses) CHILD and ADOLESCENT under 18 years not recommended iii) Generalised Anxiety: Initial dose: 30 mg OD with or without food Maintenance dose: 60 mg OD | |
| 545 | Dupilumab 200mg Solution for Injection in Prefilled Syringe | D11AH05-000-P50-01-xxx | A* | i) Dupilumab is indicated in adults and adolescents 12 years and older as an add on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO). Dupilumab is indicated as maintenance therapy for oral corticosteroid-dependent asthma. ii) Treatment of paediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids. | Indication i): i.Raised blood eosinophils (150 cells/microlitre or more) and/or raised (25 parts per billion or more) fraction of exhaled nitric oxide (FeNO). ii.To be prescribed by Respiratory Physician (Pulmonologist) only Indication ii): i. As a fourth-line treatment for patients aged 6 months to 11 years who have failed, have contraindications to, are unsuitable for, or have experienced adverse events from: • Intensive and optimised topical treatment; AND • Phototherapy; AND • At least one conventional immunosuppressant. ii. To be prescribed by Dermatologists or Paediatric Dermatologists only | Indication i): • An initial dose of 400 mg (two 200 mg injections) followed by 200 mg given every other week as subcutaneous injection • For patients with severe asthma and who are on oral corticosteroids or for patients with severe asthma and co-morbid moderate-to-severe atopic dermatitis or adults witsh co-morbid severe chronic rhinosinusitis with nasal polyposis, an initial dose of 600 mg (two 300 mg injections), followed by 300 mg every other week as subcutaneous injection Indication ii): Dosage of dupilumab for paediatric patients aged 6 months to 5 years: • 5 to less than 15 kg: 200 mg every 4 weeks (Q4W) • 15 to less than 30 kg: 300 mg every 4 weeks (Q4W) (For paediatric patients 6 months to 5 years of age with atopic dermatitis, no initial loading dose is recommended) Dosing in paediatric patients (age 6 to 11 years): • 15 to less than 30 kg: Initial dose of 600 mg followed by 300 mg every 4 weeks (Q4W) • 30 to less than 60 kg: Initial dose of 400 mg followed by 200 mg every other week (Q2W) • 60 kg or more: Initial dose of 600 mg followed by 300 mg every other week (Q2W) |
| 546 | Dupilumab 300mg Solution for Injection in Pre-filled Syringe | D11AH05-000-P50-01-XXX | A* | i) Indicated for the treatment of adult patients with severe atopic dermatitis (AD) whose disease is not adequately controlled with systemic immunosuppressants and / or phototherapy or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids. ii) Dupilumab is indicated in adults and adolescents 12 years and older as an add on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO). Dupilumab is indicated as maintenance therapy for oral corticosteroid-dependent asthma. iii) Treatment of paediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids. | Indication i): i. As fourth line of treatment in patients who have failed / have contraindications / experienced adverse events to: - Intensive and optimized topical treatment - Phototherapy - At least two immunosuppressants ii. To be prescribed by Dermatologists only Indication ii): i.Raised blood eosinophils (150 cells/microlitre or more) and/or raised (25 parts per billion or more) fraction of exhaled nitric oxide (FeNO). ii.To be prescribed by Respiratory Physician (Pulmonologist) only Indication iii): i. As a fourth-line treatment for patients aged 6 months to 11 years who have failed, have contraindications to, are unsuitable for, or have experienced adverse events from: • Intensive and optimised topical treatment; AND • Phototherapy; AND • At least one conventional immunosuppressant. ii. To be prescribed by Dermatologists or Paediatric Dermatologists only | Indication i): The recommended dose is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week. Indication ii): • An initial dose of 400 mg (two 200 mg injections) followed by 200 mg given every other week as subcutaneous injection • For patients with severe asthma and who are on oral corticosteroids or for patients with severe asthma and co-morbid moderate-to-severe atopic dermatitis or adults witsh co-morbid severe chronic rhinosinusitis with nasal polyposis, an initial dose of 600 mg (two 300 mg injections), followed by 300 mg every other week as subcutaneous injection Indication iii): Dosage of dupilumab for paediatric patients aged 6 months to 5 years: • 5 to less than 15 kg: 200 mg every 4 weeks (Q4W) • 15 to less than 30 kg: 300 mg every 4 weeks (Q4W) (For paediatric patients 6 months to 5 years of age with atopic dermatitis, no initial loading dose is recommended) Dosing in paediatric patients (age 6 to 11 years): • 15 to less than 30 kg: Initial dose of 600 mg followed by 300 mg every 4 weeks (Q4W) • 30 to less than 60 kg: Initial dose of 400 mg followed by 200 mg every other week (Q2W) • 60 kg or more: Initial dose of 600 mg followed by 300 mg every other week (Q2W) |
| 547 | Dutasteride 0.5mg and Tamsulosin 0.4mg Capsule | G04CA52-953-C10-01-XXX | A* | Combination therapy for the treatment of moderate to severe symptoms of BPH with: i) Large prostate (>30g) ii) Poor risk or not fit for surgery iii)Those who are awaiting their turn for surgery | None | One capsule daily |
| 548 | Dutasteride 0.5mg Capsule | G04CB02-000-C10-01-XXX | A* | Benign prostatic hyperplasia in men with an enlarged prostate gland | None | 0.5 mg daily |
| 549 | Dydrogesterone 10mg Tablet | G03DB01-110-T10-01-XXX | A/KK | i) Dysmenorrhoea ii) Endometriosis iii) Dysfunctional uterine bleeding (to arrest and to prevent bleeding) iv) Threatened abortion v) Habitual abortion vi) Post menopausal complaints (hormone replacement therapy in combination with oestrogen) | None | i) 10 mg bd from day 5 - 25 of cycle ii) 10 mg bd - tds from day 5 - 25 of the cycle or continuously iii) To arrest bleeding :10 mg bd with an estrogen once daily for 5 - 7 days, To prevent bleeding : 10 mg bd with an oestrogen once daily from day 11 - 25 of the cycle iv) 40 mg at once, then 10mg 8hrly until symptoms remit v) 10 mg bd until 20th week of pregnancy vi) 10-20 mg daily during last 12-14 days of each cycle |
| 550 | Ear Wax Softener | S02DA30-900-D10-XX-XX | B | Occlusion or partial occlusion of the external auditory meatus by soft wax or wax plug | None | Instill 5 drops into the ears. Refer product information leaflet |
| 551 | Edoxaban 30mg Film Coated Tablets | B01AF03-707-T32-02-XXX | A* | Indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, and age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). | None | The recommended dose is 60 mg edoxaban once daily. Therapy with edoxaban in NVAF patients should be continued long term. The recommended dose is 30 mg once daily in patients with one or more of the following clinical factors: • Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min) • Low body weight ≤ 60 kg • Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole. |
| 552 | Edoxaban 60mg Film Coated Tablets | B01AF03-707-T32-03-XXX | A* | Indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, and age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). | None | The recommended dose is 60 mg edoxaban once daily. Therapy with edoxaban in NVAF patients should be continued long term. The recommended dose is 30 mg once daily in patients with one or more of the following clinical factors: • Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min) • Low body weight ≤ 60 kg • Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole. |
| 553 | Edrophonium Chloride 10 mg/ml Injection | N07AA00100P3001XX | B | i) For reversal of neuromuscular block ii) Diagnosis of myasthenia gravis | i) Intravenous injection on over several minutes, 500 - 700 mcg/kg (after or with atropine sulphate 600 mcg) ii) Intravenous injection 2 mg followed by 8 mg if no response occurs within 30 seconds. CHILD: 20 mcg followed by 80 mcg/kg after 30 seconds | |
| 554 | Efavirenz 100mg Capsule | J05AG03-000-C10-02-XXX | A* | Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs) | None | ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg |
| 555 | Efavirenz 200mg Capsule | J05AG03-000-C10-03-XXX | A/KK | Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs) | None | ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg |
| 556 | Efavirenz 200mg Tablet | J05AG03-000-T10-03-XXX | A/KK | Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs) | - | ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg |
| 557 | Efavirenz 50mg Capsule | J05AG03-000-C10-01-XXX | A* | Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs) | None | ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg |
| 558 | Efavirenz 600mg Tablet | J05AG03-000-T10-01-XXX | A/KK | Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs) | None | ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg |
| 559 | Eltrombopag Olamine 25 mg Film-coated Tablet | B02BX05999T1001XX | A* | Short term use in idiopathic thrombocytopenic purpura patients as bridging therapy for splenectomy or surgery and in cases of severe bleeding. | Individualised dosage based on the patient's platelet count. ADULT: Initially 50 mg once daily. East-/Southeast-Asian ancestry: 25 mg once daily. Then, adjust dose to maintain platelet count ≥50,000/microliter. Max: 75 mg daily. Dosing is individualised and according to product insert/protocol. | |
| 560 | Emicizumab 150mg/ml solution for Injection | B02BX06-000-P30-02-XXX | A* | i. For routine prophylaxis of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors ii. For routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency), without factor VIII inhibitors who have, severe disease (FVIII < 1%) | Indikasi i: To be prescribed by consultant haematologists only Indikasi ii: 1. For paediatric patients aged 8 years and below 2. To be prescribed by Consultant Haematologists only | 3 mg/kg once weekly for the first 4 weeks (loading dose), followed by maintenance dose of either 1.5 mg/kg once weekly, 3 mg/kg every two weeks, or 6 mg/kg every four weeks |
| 561 | Emicizumab 30mg/ml solution for injection | B02BX06-000-P30-01-XXX | A* | i. For routine prophylaxis of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors ii. For routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency), without factor VIII inhibitors who have, severe disease (FVIII < 1%) | Indikasi i: To be prescribed by consultant haematologists only Indikasi ii: 1. For paediatric patients aged 8 years and below 2. To be prescribed by Consultant Haematologists only | 3 mg/kg once weekly for the first 4 weeks (loading dose), followed by maintenance dose of either 1.5 mg/kg once weekly, 3 mg/kg every two weeks, or 6 mg/kg every four weeks |
| 562 | Empagliflozin 10mg tablet | A10BK03-000-T32-01-XXX | A/KK | Indication 1: Indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as: Add-on combination therapy: In combination with other glucose–lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Indication 2: Indicated in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD) to reduce the risk of cardiovascular (CV) death: As an adjunct to diet, exercise and standard of care, to reduce the risk of cardiovascular (CV) death. Indication 3: Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV). Indication 4: For cardiorenal protection in adult patients with chronic kidney disease, with or without type 2 diabetes mellitus, with eGFR ≥20mL/min/1.73m2, or eGFR at least 45mL/min/1.73m2 with a urinary albumin-to-creatinine ratio of ≥200mg/g receiving maximal tolerated treatment with ACEi or ARB. | Indication 1: Patients with HbA1c between 6.5%-10.0% while on single / combination anti-diabetic therapy. Indication 2: Patients with HbA1c not more than 10.0% while on adequate trial of metformin. Indication 3: i. Treatment to be initiated in hospital setting before continuation of treatment for stable patients by Family Medicine Specialist (FMS) in the primary care setting. ii. All patients must be counselled regarding risk of euglycemic ketoacidosis before initiation of treatment | Indication 1 & 2: - Starting dose is 10 mg empagliflozin once daily for monotherapy and add-on combination therapy with other glucose-lowering medicinal products including insulin. - In patients tolerating empagliflozin 10 mg once daily and need tighter glycaemic control, the dose can be increased to 25 mg once daily. - The maximum daily dose is 25 mg. Indication 3 & 4: 10mg once daily |
| 563 | Empagliflozin 25mg tablet | A10BK03-000-T32-02-XXX | A/KK | Indication 1: Indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as: Add-on combination therapy: In combination with other glucose–lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Indication 2: Indicated in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD) to reduce the risk of cardiovascular (CV) death: As an adjunct to diet, exercise and standard of care, to reduce the risk of cardiovascular (CV) death. | Indication 1: Patients with HbA1c between 6.5%-10.0% while on single / combination anti-diabetic therapy. Indication 2: Patients with HbA1c not more than 10.0% while on adequate trial of metformin. | - Starting dose is 10 mg empagliflozin once daily for monotherapy and add-on combination therapy with other glucose-lowering medicinal products including insulin. - In patients tolerating empagliflozin 10 mg once daily and need tighter glycaemic control, the dose can be increased to 25 mg once daily. - The maximum daily dose is 25 mg |
| 564 | Emulsificants Ointment | D02AC00-952-G50-01-XXX | C | As an emollient for the symptomatic relief of dry skin conditions and as soap-substitute for skin-bathing. | None | Apply to the affected area as required or as in package insert |
| 565 | Enalapril 10mg Tablet | C09AA02-253-T10-02-XX | B | i) Hypertension ii) Heart failure iii) Prevention of coronary ischemic events in patients with left ventricular dysfunction | None | i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max. 40mg daily in 1-2 divided doses ii) & iii) Initial: 2.5mg once daily Maintenance: 20mg in 1-2 divided doses Max. 40mg daily in 2 divided doses Dosing is individualised and according to product insert / protocol. |
| 566 | Enalapril 20mg Tablet | C09AA02-253-T10-03-XX | B | i) Hypertension ii) Heart failure iii) Prevention of coronary ischemic events in patients with left ventricular dysfunction | None | i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max. 40mg daily in 1-2 divided doses ii) & iii) Initial: 2.5mg once daily Maintenance: 20mg in 1-2 divided doses Max. 40mg daily in 2 divided doses Dosing is individualised and according to product insert / protocol. |
| 567 | Enalapril 5mg Tablet | C09AA02253T1001XX | B | i) Hypertension ii) Heart failure iii) Prevention of coronary ischemic events in patients with left ventricular dysfunction | None | i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max. 40mg daily in 1-2 divided doses ii) & iii) Initial: 2.5mg once daily Maintenance: 20mg in 1-2 divided doses Max. 40mg daily in 2 divided doses Dosing is individualised and according to product insert / protocol. |
| 568 | Enoxaparin Sodium 20 mg Injection | B01AB05520P5001XX | A*, A/KK | KATEGORI PRESKRIBER A*: i. Prophylaxis of venous thromboembolic diseases (DVT and PE) especially in perioperative, high risk surgical cases and medical patients with acute illness at increased risk of VTE ii. Treatment of venous thromboembolic diseases (DVT and PE). iii. Acute coronary syndrome: a. Treatment of unstable angina and Non-ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid. b. Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI). KATEGORI PRESKRIBER A/KK: Prevention of DVT in antenatal and/or postnatal women with VTE risk scoring of 3 or more. A written consent form by the patient is necessary prior treatment initiation. Healthcare facilities are advised to refer to “Panduan Penggunaan Ubat- Ubatan yang Mengandungi Unsur Tidak Halal”. | KATEGORI PRESKRIBER A* i. Moderate risk: 20mg SC 2 hours before surgery then 20mg SC once daily High risk: 40mg SC 12 hours before surgery then 40mg SC once daily Medical patients: 40mg once daily ii. 1.5mg/kg once daily or 1mg/kg twice daily iii. 1 mg/kg every 12 hours KATEGORI PRESKRIBER A/KK: <50 kg: 20mg OD 50-90 kg: 40mg OD 91-130 kg: 60mg OD 131-170 kg: 80mg OD >170 kg: 0.6mg/kg/day | |
| 569 | Enoxaparin Sodium 40 mg Injection | B01AB05520P5002XX | A*, A/KK | KATEGORI PRESKRIBER A*: i. Prophylaxis of venous thromboembolic diseases (DVT and PE) especially in perioperative, high risk surgical cases and medical patients with acute illness at increased risk of VTE ii. Treatment of venous thromboembolic diseases (DVT and PE). iii. Acute coronary syndrome: a. Treatment of unstable angina and Non-ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid. b. Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI). KATEGORI PRESKRIBER A/KK: Prevention of DVT in antenatal and/or postnatal women with VTE risk scoring of 3 or more. A written consent form by the patient is necessary prior treatment initiation. Healthcare facilities are advised to refer to “Panduan Penggunaan Ubat- Ubatan yang Mengandungi Unsur Tidak Halal”. | KATEGORI PRESKRIBER A* i. Moderate risk: 20mg SC 2 hours before surgery then 20mg SC once daily High risk: 40mg SC 12 hours before surgery then 40mg SC once daily Medical patients: 40mg once daily ii. 1.5mg/kg once daily or 1mg/kg twice daily iii. 1 mg/kg every 12 hours KATEGORI PRESKRIBER A/KK: <50 kg: 20mg OD 50-90 kg: 40mg OD 91-130 kg: 60mg OD 131-170 kg: 80mg OD >170 kg: 0.6mg/kg/day | |
| 570 | Enoxaparin Sodium 60 mg Injection | B01AB05520P5003XX | A*, A/KK | KATEGORI PRESKRIBER A*: i. Prophylaxis of venous thromboembolic diseases (DVT and PE) especially in perioperative, high risk surgical cases and medical patients with acute illness at increased risk of VTE ii. Treatment of venous thromboembolic diseases (DVT and PE). iii. Acute coronary syndrome: a. Treatment of unstable angina and Non-ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid. b. Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI). KATEGORI PRESKRIBER A/KK: Prevention of DVT in antenatal and/or postnatal women with VTE risk scoring of 3 or more. A written consent form by the patient is necessary prior treatment initiation. Healthcare facilities are advised to refer to “Panduan Penggunaan Ubat- Ubatan yang Mengandungi Unsur Tidak Halal”. | KATEGORI PRESKRIBER A* i. Moderate risk: 20mg SC 2 hours before surgery then 20mg SC once daily High risk: 40mg SC 12 hours before surgery then 40mg SC once daily Medical patients: 40mg once daily ii. 1.5mg/kg once daily or 1mg/kg twice daily iii. 1 mg/kg every 12 hours KATEGORI PRESKRIBER A/KK: <50 kg: 20mg OD 50-90 kg: 40mg OD 91-130 kg: 60mg OD 131-170 kg: 80mg OD >170 kg: 0.6mg/kg/day |